Trevi Therapeutics Inc

NASDAQ:TRVIUnited States

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Contact Information

Headquarters

195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009

Phone

203-304-2499

Fax

203-304-2434

Executives

Non-Executive Chairman of the Board

David Meeker

President, Chief Executive Officer, Director

Jennifer Good

Co-Founder, Chief Science Officer

Thomas Sciascia

Chief Financial Officer

Lisa Delfini

Chief Development Officer

James Cassella